Signaturefd LLC Lowers Stake in Neurocrine Biosciences, Inc. $NBIX

Signaturefd LLC lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report) by 24.9% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 1,833 shares of the company’s stock after selling 607 shares during the period. Signaturefd LLC’s holdings in Neurocrine Biosciences were worth $230,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in NBIX. Wealth Enhancement Advisory Services LLC boosted its position in shares of Neurocrine Biosciences by 199.1% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,886 shares of the company’s stock worth $2,305,000 after purchasing an additional 11,240 shares during the period. Versant Capital Management Inc boosted its position in shares of Neurocrine Biosciences by 404.9% during the 1st quarter. Versant Capital Management Inc now owns 409 shares of the company’s stock worth $45,000 after purchasing an additional 328 shares during the period. GAMMA Investing LLC boosted its position in shares of Neurocrine Biosciences by 9,446.8% during the 1st quarter. GAMMA Investing LLC now owns 219,099 shares of the company’s stock worth $24,232,000 after purchasing an additional 216,804 shares during the period. Merit Financial Group LLC boosted its position in shares of Neurocrine Biosciences by 9.1% during the 1st quarter. Merit Financial Group LLC now owns 4,153 shares of the company’s stock worth $459,000 after purchasing an additional 345 shares during the period. Finally, Hennion & Walsh Asset Management Inc. boosted its position in shares of Neurocrine Biosciences by 22.1% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 6,307 shares of the company’s stock worth $698,000 after purchasing an additional 1,140 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Trading Down 0.2%

Shares of NBIX opened at $136.74 on Friday. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $154.61. The firm’s fifty day simple moving average is $136.89 and its 200-day simple moving average is $124.00. The firm has a market capitalization of $13.56 billion, a price-to-earnings ratio of 40.46, a PEG ratio of 0.99 and a beta of 0.21.

Neurocrine Biosciences (NASDAQ:NBIXGet Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.98 by $0.08. Neurocrine Biosciences had a net margin of 13.88% and a return on equity of 13.22%. The firm had revenue of $687.50 million for the quarter, compared to analyst estimates of $653.09 million. During the same period last year, the business earned $1.63 EPS. Neurocrine Biosciences’s revenue for the quarter was up 16.5% compared to the same quarter last year. On average, analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on NBIX. Piper Sandler increased their target price on shares of Neurocrine Biosciences from $154.00 to $175.00 and gave the stock an “overweight” rating in a report on Thursday, July 31st. Needham & Company LLC increased their target price on shares of Neurocrine Biosciences from $161.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, September 22nd. Stifel Nicolaus increased their target price on shares of Neurocrine Biosciences from $166.00 to $174.00 and gave the stock a “buy” rating in a report on Thursday, July 31st. The Goldman Sachs Group began coverage on shares of Neurocrine Biosciences in a report on Thursday, July 10th. They set a “buy” rating and a $182.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, September 22nd. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $161.89.

View Our Latest Research Report on NBIX

Insider Buying and Selling

In related news, Director Kevin Charles Gorman sold 106,322 shares of the firm’s stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $126.41, for a total value of $13,440,164.02. Following the completion of the sale, the director owned 514,596 shares in the company, valued at $65,050,080.36. This trade represents a 17.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jude Onyia sold 59,819 shares of the firm’s stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $130.46, for a total transaction of $7,803,986.74. Following the completion of the sale, the insider owned 18,289 shares of the company’s stock, valued at approximately $2,385,982.94. The trade was a 76.58% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 166,598 shares of company stock worth $21,305,846 in the last ninety days. 4.80% of the stock is owned by corporate insiders.

Neurocrine Biosciences Profile

(Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Recommended Stories

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.